Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE.
MAbs. 2021 Jan-Dec;13(1):1903664. doi: 10.1080/19420862.2021.1903664.
Today's biologics manufacturing practices incur high costs to the drug makers, which can contribute to high prices for patients. Timely investment in the development and implementation of continuous biomanufacturing can increase the production of consistent-quality drugs at a lower cost and a faster pace, to meet growing demand. Efficient use of equipment, manufacturing footprint, and labor also offer the potential to improve drug accessibility. Although technological efforts enabling continuous biomanufacturing have commenced, challenges remain in the integration, monitoring, and control of traditionally segmented unit operations. Here, we discuss recent developments supporting the implementation of continuous biomanufacturing, along with their benefits.
今天的生物制品制造实践给制药商带来了高昂的成本,这可能导致患者的价格高昂。及时投资于连续生物制造的开发和实施,可以以更低的成本和更快的速度增加一致质量药物的生产,以满足不断增长的需求。设备、制造足迹和劳动力的高效利用也有可能提高药物的可及性。尽管实现连续生物制造的技术努力已经开始,但在传统分段单元操作的集成、监测和控制方面仍存在挑战。在这里,我们讨论了支持连续生物制造实施的最新进展及其带来的好处。